|

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

RECRUITINGPhase 1Sponsored by Deciphera Pharmaceuticals, LLC
Actively Recruiting
PhasePhase 1
SponsorDeciphera Pharmaceuticals, LLC
Started2025-08-27
Est. completion2029-02
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations3 sites
View on ClinicalTrials.gov →

NCT06966024

Summary

This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Key Inclusion Criteria:

* Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
* Able to take oral medication
* If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements
* Adequate organ function and electrolytes

Key Exclusion Criteria:

* Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812
* Impaired cardiac function
* Major surgery within 28 days of the first dose of study drug

Conditions4

CancerCastration-resistant Prostate CancerRenal Cell CarcinomaUrothelial Carcinoma

Locations3 sites

Massachusetts

1 site
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
Bicky Thapa, MD617-632-3000bicky_thapa@dfci.harvard.edu

Texas

2 sites
NEXT Oncology, Austin
Austin, Texas, 78758
Clinical Trial Navigator737-610-5180hwatson@nextoncology.com
NEXT Oncology, San Antonio
San Antonio, Texas, 78229
Jordan Georg210-580-9521jgeorg@nextoncology.com

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.